Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, agosto 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Intellia Therapeutics Inc
NTLA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$13.19
-0.32
-2.37%
In chiusura: Aug 26, 5:00 PM EST
$13.19
N/A
Post-mercato: 4:00 PM EST
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Intellia Therapeutics Financials
Intellia Therapeutics (NTLA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses of $(0.98) per
Benzinga Newsdesk
PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share
Benzinga Newsdesk
PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share
Benzinga Newsdesk
PRO
Intellia Therapeutics Q4 EPS $(0.83) Beats $(0.96) Estimate, Sales $23.017M Beat $12.812M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.96) by 13.72 percent. This is a 34.65 percent increase over losses of $(1.27) per share
Benzinga Newsdesk
Earnings Scheduled For February 26, 2026
Benzinga Insights
Earnings Preview For Intellia Therapeutics
Benzinga Insights
Privacy Manager